SABCS Updates on TNBC: Chemotherapy, Biomarkers, PARPi, AKTi, CDK4/6i, Sacituzumab Govitecan, Neoadjuvant Atezolizumab & Pembrolizumab
By
CECOG Academy
FEATURING
Rupert Bartsch
By
CECOG Academy
FEATURING
Rupert Bartsch
Comments 0
Login to view comments.
Click here to Login
